ABBOTT LABORATORIES — M&A Activity 2015

Feb 27, 2015

8-K 1 a15-4186_18k.htm 8-K

*UNITED STATES*

*SECURITIES AND EXCHANGE COMMISSION*

*WASHINGTON, D.C. 20549*

*FORM 8-K*

*CURRENT REPORT*

*Pursuant to Section 13 or 15(d) of the*

*Securities Exchange Act of 1934*

Date of Report (Date of earliest event reported): February 27, 2015

*Abbott Laboratories*

(Exact name of registrant as specified in its charter)

Illinois	1-2189	36-0698440
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

*100 Abbott Park Road*

*Abbott Park, Illinois 60064-6400*

(Address of principal executive offices)(Zip Code)

Registrant’s telephone number, including area code: (224) 667-6100

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

SEQ.=1,FOLIO='',FILE='C:\JMS\108750\15-4186-1\task7238864\4186-1-ba.htm',USER='108750',CD='Feb 27 10:50 2015'

*Item 2.01 Completion of Acquisition or Disposition of Assets.*

On February 27, 2015, Abbott completed the sale of its developed markets branded generics pharmaceuticals business to Mylan in exchange for 110 million ordinary shares of Mylan N.V.

*Item 9.01 Financial Statements and Exhibits.*

(b) To be provided by amendment.

(d) Exhibits

Exhibit No.	Exhibit
2.1	Amended and Restated Business Transfer Agreement dated as of November 4, 2014 (incorporated by reference to Exhibit 2.1 to the Quarterly Report on Form 10-Q filed by Abbott Laboratories with the Securities and Exchange Commission on November 5, 2014)

2

SEQ.=1,FOLIO='2',FILE='C:\JMS\108750\15-4186-1\task7238864\4186-1-ba.htm',USER='108750',CD='Feb 27 10:50 2015'

*SIGNATURES*

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: February 27, 2015
By:	/s/ Thomas C. Freyman
	Thomas C. Freyman
	Executive Vice President, Finance and Chief Financial Officer

3

SEQ.=1,FOLIO='3',FILE='C:\JMS\108750\15-4186-1\task7238864\4186-1-ba.htm',USER='108750',CD='Feb 27 10:50 2015'

*EXHIBIT INDEX*

Exhibit No.	Exhibit
2.1	Amended and Restated Business Transfer Agreement dated as of November 4, 2014 (incorporated by reference to Exhibit 2.1 to the Quarterly Report on Form 10-Q filed by Abbott Laboratories with the Securities and Exchange Commission on November 5, 2014)

4

SEQ.=1,FOLIO='4',FILE='C:\JMS\108750\15-4186-1\task7238864\4186-1-ba.htm',USER='108750',CD='Feb 27 10:50 2015'